Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro.

Lane T, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S.

Pharm Res. 2019 May 17;36(7):104. doi: 10.1007/s11095-019-2629-0.

PMID:
31101988
2.

Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads.

Anantpadma M, Lane T, Zorn KM, Lingerfelt MA, Clark AM, Freundlich JS, Davey RA, Madrid PB, Ekins S.

ACS Omega. 2019 Jan 31;4(1):2353-2361. doi: 10.1021/acsomega.8b02948. Epub 2019 Jan 30.

3.

Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication.

Batra J, Hultquist JF, Liu D, Shtanko O, Von Dollen J, Satkamp L, Jang GM, Luthra P, Schwarz TM, Small GI, Arnett E, Anantpadma M, Reyes A, Leung DW, Kaake R, Haas P, Schmidt CB, Schlesinger LS, LaCount DJ, Davey RA, Amarasinghe GK, Basler CF, Krogan NJ.

Cell. 2018 Dec 13;175(7):1917-1930.e13. doi: 10.1016/j.cell.2018.08.044.

PMID:
30550789
4.

Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus.

Cui Q, Cheng H, Xiong R, Zhang G, Du R, Anantpadma M, Davey RA, Rong L.

Viruses. 2018 Nov 30;10(12). pii: E678. doi: 10.3390/v10120678.

5.

Novel amodiaquine derivatives potently inhibit Ebola virus infection.

Sakurai Y, Sakakibara N, Toyama M, Baba M, Davey RA.

Antiviral Res. 2018 Dec;160:175-182. doi: 10.1016/j.antiviral.2018.10.025. Epub 2018 Nov 3.

PMID:
30395872
6.

Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.

Luthra P, Naidoo J, Pietzsch CA, De S, Khadka S, Anantpadma M, Williams CG, Edwards MR, Davey RA, Bukreyev A, Ready JM, Basler CF.

Antiviral Res. 2018 Oct;158:288-302. doi: 10.1016/j.antiviral.2018.08.012. Epub 2018 Aug 23.

PMID:
30144461
7.

Autophagy-Associated Proteins Control Ebola Virus Internalization Into Host Cells.

Shtanko O, Reyes AN, Jackson WT, Davey RA.

J Infect Dis. 2018 Nov 22;218(suppl_5):S346-S354. doi: 10.1093/infdis/jiy294.

8.

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.

Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA.

J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093/infdis/jiy285.

9.

Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor.

Cui Q, Du R, Anantpadma M, Schafer A, Hou L, Tian J, Davey RA, Cheng H, Rong L.

Viruses. 2018 Mar 27;10(4). pii: E152. doi: 10.3390/v10040152.

10.

Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection.

Shtanko O, Sakurai Y, Reyes AN, Noël R, Cintrat JC, Gillet D, Barbier J, Davey RA.

Antiviral Res. 2018 Jan;149:154-163. doi: 10.1016/j.antiviral.2017.11.016. Epub 2017 Nov 22.

11.

ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments.

Wu Y, Pons V, Goudet A, Panigai L, Fischer A, Herweg JA, Kali S, Davey RA, Laporte J, Bouclier C, Yousfi R, Aubenque C, Merer G, Gobbo E, Lopez R, Gillet C, Cojean S, Popoff MR, Clayette P, Le Grand R, Boulogne C, Tordo N, Lemichez E, Loiseau PM, Rudel T, Sauvaire D, Cintrat JC, Gillet D, Barbier J.

Sci Rep. 2017 Nov 14;7(1):15567. doi: 10.1038/s41598-017-15466-7.

12.

Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Leishmania and Chlamydiales.

Gupta N, Noël R, Goudet A, Hinsinger K, Michau A, Pons V, Abdelkafi H, Secher T, Shima A, Shtanko O, Sakurai Y, Cojean S, Pomel S, Liévin-Le Moal V, Leignel V, Herweg JA, Fischer A, Johannes L, Harrison K, Beard PM, Clayette P, Le Grand R, Rayner JO, Rudel T, Vacus J, Loiseau PM, Davey RA, Oswald E, Cintrat JC, Barbier J, Gillet D.

Chem Biol Interact. 2017 Apr 1;267:96-103. doi: 10.1016/j.cbi.2016.10.005. Epub 2016 Oct 3.

PMID:
27712998
13.

Corrigendum: Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining.

Wang B, Kluwe CA, Lungu OI, DeKosky BJ, Kerr SA, Johnson EL, Tanno H, Lee CH, Jung J, Rezigh AB, Carroll SM, Reyes AN, Bentz JR, Villanueva I, Altman AL, Davey RA, Ellington AD, Georgiou G.

Sci Rep. 2016 Jun 10;6:27229. doi: 10.1038/srep27229. No abstract available.

14.

Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis and Establishes a Type 1 Interferon-Independent Antiviral State.

Chung DH, Golden JE, Adcock RS, Schroeder CE, Chu YK, Sotsky JB, Cramer DE, Chilton PM, Song C, Anantpadma M, Davey RA, Prodhan AI, Yin X, Zhang X.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4552-62. doi: 10.1128/AAC.00282-16. Print 2016 Aug.

15.

Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors.

Anantpadma M, Kouznetsova J, Wang H, Huang R, Kolokoltsov A, Guha R, Lindstrom AR, Shtanko O, Simeonov A, Maloney DJ, Maury W, LaCount DJ, Jadhav A, Davey RA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4471-81. doi: 10.1128/AAC.00543-16. Print 2016 Aug.

16.

Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro.

Cap AP, Pidcoke HF, Keil SD, Staples HM, Anantpadma M, Carrion R Jr, Davey RA, Frazer-Abel A, Taylor AL, Gonzales R, Patterson JL, Goodrich RP.

Transfusion. 2016 Mar;56 Suppl 1:S6-15. doi: 10.1111/trf.13393.

17.

Interferon-γ Inhibits Ebola Virus Infection.

Rhein BA, Powers LS, Rogers K, Anantpadma M, Singh BK, Sakurai Y, Bair T, Miller-Hunt C, Sinn P, Davey RA, Monick MM, Maury W.

PLoS Pathog. 2015 Nov 12;11(11):e1005263. doi: 10.1371/journal.ppat.1005263. eCollection 2015.

18.

Machine learning models identify molecules active against the Ebola virus in vitro.

Ekins S, Freundlich JS, Clark AM, Anantpadma M, Davey RA, Madrid P.

Version 3. F1000Res. 2015 Oct 20 [revised 2017 Jan 1];4:1091. doi: 10.12688/f1000research.7217.3. eCollection 2015.

19.

Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining.

Wang B, Kluwe CA, Lungu OI, DeKosky BJ, Kerr SA, Johnson EL, Tanno H, Lee CH, Jung J, Rezigh AB, Carroll SM, Reyes AN, Bentz JR, Villanueva I, Altman AL, Davey RA, Ellington AD, Georgiou G.

Sci Rep. 2015 Sep 10;5:13926. doi: 10.1038/srep13926. Erratum in: Sci Rep. 2016 Jun 10;6:27229.

20.

An Intrinsically Disordered Peptide from Ebola Virus VP35 Controls Viral RNA Synthesis by Modulating Nucleoprotein-RNA Interactions.

Leung DW, Borek D, Luthra P, Binning JM, Anantpadma M, Liu G, Harvey IB, Su Z, Endlich-Frazier A, Pan J, Shabman RS, Chiu W, Davey RA, Otwinowski Z, Basler CF, Amarasinghe GK.

Cell Rep. 2015 Apr 21;11(3):376-89. doi: 10.1016/j.celrep.2015.03.034. Epub 2015 Apr 9.

Supplemental Content

Loading ...
Support Center